PharmaMar presents at ASCO the ADMYRE study's adjusted overall survival with plitidepsin

(Pharmamar) PharmaMar (MSE:PHM) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after receiving dexamethasone as a single agent and who were subsequently treated with plitidepsin in combination with dexamethasone was analyzed. Of the 84 patients treated from the comparator arm -dexamethasone as a single agent- 44 percent, 37 patients were treated with the combination with plitidepsi...